Compare J B Hunt Transport Services Inc (JBHT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs TG Therapeutics Inc — how do they compare? J B Hunt Transport Services Inc trades at $265.38 (market cap $24.92B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: J B Hunt Transport Services Inc is far larger — about 3.3× TG Therapeutics Inc's market cap, and J B Hunt Transport Services Inc pays a 0.68% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| JBHT | TGTX | |
|---|---|---|
Market Cap | $24.92B | $7.64B |
Sector | Industrials | Health |
52-Week High | $298.41 | $59.06 |
52-Week Low | $130.65 | $26.94 |
Enterprise Value | $26.06B | $7.84B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $275.86, up 3.65% today, with a bearish technical signal but strong analyst support. Recent quarters show earnings beats, with Q3 2026 expected at $2.12 EPS. Revenue is projected to grow to $12.7B in 2026, with a net income margin of 5.31%. The company maintains solid profitability metrics, including an 18.45% ROE, and announced a $0.45 dividend payable in August 2026.
The outlook is mixed; strong fundamentals and a $299.82 consensus price target suggest upside, but bearish technicals and competitive pressures pose risks. Investors should weigh earnings consistency against market volatility and sector headwinds for balanced exposure.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
